Alliance Pharma director plans share acquisition

Published 23/04/2025, 09:26
Alliance Pharma director plans share acquisition

LONDON - Alliance Pharma (LON:ALAPH) plc has disclosed that one of its directors, Richard McKenzie, intends to acquire 23,000 shares of the company, representing a 0.004% stake, on or after April 24, 2025. This move comes following the announcement on January 10, 2025, of a recommended acquisition of Alliance by Aegros Bidco Limited, a company to be indirectly owned by affiliates of DBAY Advisors Limited and the ERES IV Fund.

The acquisition, which is proposed to be executed through a Court-sanctioned scheme of arrangement, was detailed in a circular on January 31, 2025, and later updated with a final increased cash offer on March 10, 2025. McKenzie’s planned share purchase is a precursor to electing the Alternative Offer, which would allow him to maintain an interest in Alliance as a private company and potentially partake in future value creation, though this outcome is not guaranteed.

The director’s acquisition plan provides at least 24 hours of public notice in compliance with Rule 4.2 of the Takeover Code. However, Alliance’s board cannot advise on the fairness of the Alternative Offer and has not recommended any action to shareholders regarding this option. Shareholders are urged to consider the advantages, disadvantages, and risk factors associated with the Alternative Offer as outlined in the Scheme Document.

This announcement is based on a press release statement, which serves as the source of this information.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.